Nivolumab Products (Opdivo, Opdivo Qvantig, and Opdualag) | AETNA Coverage Update

Summary: Aetna, a CVS Health company, modified CPB 0892 covering nivolumab products (Opdivo, Opdivo Qvantig, and Opdualag), effective April 11, 2026. Here's what billing teams need to do.

Aetna updated its nivolumab coverage policy under CPB 0892 Aetna on April 11, 2026. This policy governs reimbursement for three branded immunotherapy agents: nivolumab (Opdivo), nivolumab and relatlimab-rmbw (Opdualag), and subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig). The policy document does not list specific CPT or HCPCS codes, so your billing team should verify applicable codes directly against your current charge capture and Aetna's published fee schedule.

Quick-Reference Table

Aetna Nivolumab Coverage Criteria and Medical Necessity Requirements 2026

Nivolumab billing sits in a high-scrutiny category for Aetna. These are expensive oncology agents, and Aetna's coverage policy for them is detailed by indication. A claim that doesn't map precisely to an approved indication will get denied — full stop.

CPB 0892 covers all three products in the nivolumab family, but they are not interchangeable from a coverage standpoint. Opdivo (intravenous nivolumab) has the longest FDA approval history and the broadest indication list. Opdualag pairs nivolumab with relatlimab and carries its own distinct approval footprint. Opdivo Qvantig is the subcutaneous formulation and is the newest entry — expect tighter scrutiny on medical necessity documentation until Aetna's coverage policy matures around it.

Because the source policy document for this April 11, 2026 modification does not include a detailed summary of criteria, billing teams should pull the full CPB 0892 text directly from Aetna's clinical policy bulletins. Do not rely on the previous version of this policy. Changes between versions can shift which indications require prior authorization and which are excluded outright.

What Typically Drives Medical Necessity for Nivolumab Products

Aetna's medical necessity determinations for PD-1 inhibitors like nivolumab typically hinge on several factors. First, the specific FDA-approved indication must match the documented diagnosis. Second, prior therapy requirements — whether a patient must have failed one or more prior lines of treatment — vary by indication and can change when FDA labeling updates. Third, biomarker testing results (PD-L1 expression, TMB, MSI-H status) often factor into coverage criteria depending on the tumor type.

Prior authorization is required for all three of these products under commercial Aetna plans. That is not new, but the criteria tied to each auth request may have shifted with this April 11, 2026 update. Submit authorization requests with complete clinical documentation: pathology reports, biomarker results, staging, and prior treatment history.

Aetna Nivolumab Exclusions and Non-Covered Indications

Aetna's coverage policy for nivolumab products draws a clear line between FDA-approved uses and off-label ones. Off-label use of these agents is not automatically covered, even when clinical evidence exists.

Combinations not supported by FDA labeling or NCCN compendium recognition are the most common source of claim denial in this category. If your oncology team is using Opdivo or Opdualag in a combination regimen that isn't explicitly listed in Aetna's CPB 0892 criteria, expect a denial without a strong prior auth submission backed by peer-reviewed literature.

Opdivo Qvantig (the subcutaneous formulation) deserves special attention here. Subcutaneous routes for agents previously approved only for IV delivery sometimes face additional coverage hurdles. Aetna may require documentation that the subcutaneous formulation is medically appropriate and that the indication mirrors an approved IV indication. Verify this before switching a patient from Opdivo IV to Opdivo Qvantig — the reimbursement path is not always equivalent.

Coverage Indications at a Glance

Because the April 11, 2026 policy document does not include a detailed indication list, the table below reflects the known FDA-approved indication categories for these three products as of this update. Confirm each row against the full CPB 0892 text before billing.

Source: FDA prescribing information and known Aetna CPB 0892 coverage patterns. Confirm all rows against the April 11, 2026 CPB 0892 text.

Aetna Nivolumab Billing Guidelines and Action Items 2026

CPT, HCPCS, and ICD-10 Codes for Nivolumab Products Under CPB 0892

The April 11, 2026 version of CPB 0892 does not include a specific code list in the available policy data. The policy document does not enumerate CPT, HCPCS, or ICD-10 codes in the source reviewed for this post.

This is worth flagging. For high-cost oncology drugs, Aetna typically ties coverage criteria to specific HCPCS J-codes for the drug and to relevant ICD-10 diagnosis codes by indication. The absence of a code list in this data source does not mean codes are absent from the full policy bulletin.

What your billing team should do:

• Access the full CPB 0892 document directly at Aetna's clinical policy site to get the complete code list
• Confirm HCPCS codes for all three products with your drug pricing database (e.g., Medispan, Medi-Span, or your GPO)
• Do not use codes not validated against the April 11, 2026 policy version — especially for Opdivo Qvantig, where HCPCS assignment may differ from the IV formulation

If your billing consultant or oncology coder hasn't reviewed the full CPB 0892 text against your current charge description master, do that before you submit claims under the new effective date.